Quantcast
Last updated on April 16, 2014 at 13:31 EDT

Latest Kite Pharma Inc. Stories

2014-04-14 12:33:40

SANTA MONICA, Calif., April 14, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Ms. Cynthia M. Butitta has been appointed its Chief Operating Officer in addition to serving in her current role as Chief Financial Officer. Further, Dr. Margo R. Roberts, Ph.D., has been promoted to Chief Scientific Officer....

2014-04-11 08:24:38

SANTA MONICA, Calif., April 11, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of Jonathan M. Peacock, former Chief Financial Officer of Amgen, to the Company's Board of Directors. Mr. Peacock's appointment is effective immediately, bringing the number of Kite's directors to eight. Arie Belldegrun,...

2014-04-02 12:31:14

SANTA MONICA, Calif., April 2, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for cancer, today announced the appointment of Arie Belldegrun, M.D., FACS, as President and Chief Executive Officer. Dr. Belldegrun, who is also a founder of Kite, will continue in his current role as Chairman of the Company. "Dr. Belldegrun has had a distinguished 18-year tenure in...

2014-03-31 08:29:19

SANTA MONICA, Calif., March 31, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for...

2014-01-17 08:23:09

LOS ANGELES, Jan. 17, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for cancer, today announced the appointment of Rizwana F. Sproule, Ph.D., to the newly created position of Vice President, Regulatory Affairs. Dr. Sproule has over 16 years of experience in regulatory affairs for both biologics and small molecule therapeutics across multiple therapeutic areas. Her...

2014-01-08 08:28:29

LOS ANGELES, Jan. 8, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for cancer, today announced the appointment of Cynthia M. Butitta to the newly created position of Executive Vice President and Chief Financial Officer. A veteran financial and operational executive, Ms. Butitta brings over 20 years' experience in leadership roles in the biotech and technology...

2014-01-07 08:30:57

LOS ANGELES, Jan. 7, 2014 /PRNewswire/ -- Kite Pharma today announced that Dr. Arie Belldegrun, Executive Chairman and Founder of Kite Pharma, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 1:30 p.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20130513/MM13332LOGO ) About Kite Pharma Kite Pharma, Inc. (Kite) is a privately held...

2013-12-07 16:20:24

- Findings Presented at 55th American Society of Hematology (ASH) Annual Meeting - LOS ANGELES, Dec. 7, 2013 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite's most advanced product candidate can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma. In an oral...

2013-08-08 08:31:02

LOS ANGELES, Aug. 8, 2013 /PRNewswire/ -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of three leading experts in the areas of immunotherapy, chimeric antigen receptor (CAR) technology, and gene therapy to its Scientific Advisory Board (SAB). (Logo: http://photos.prnewswire.com/prnh/20130513/MM13332LOGO) "Kite is fortunate to attract these world-leading...

2013-05-30 08:30:14

LOS ANGELES, May 30, 2013 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of Keith Nolop, M.D. as Chief Medical Officer. Dr. Nolop, who brings to Kite over 20 years of successful drug development experience at both biotechnology and global pharmaceutical companies, was previously Senior Vice President of Development and Chief Medical Officer...